193 related articles for article (PubMed ID: 24335535)
1. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
Dugger BN; Clark CM; Serrano G; Mariner M; Bedell BJ; Coleman RE; Doraiswamy PM; Lu M; Fleisher AS; Reiman EM; Sabbagh MN; Sadowsky CH; Schneider JA; Zehntner SP; Carpenter AP; Joshi AD; Mintun MA; Pontecorvo MJ; Skovronsky DM; Sue LI; Beach TG
J Neuropathol Exp Neurol; 2014 Jan; 73(1):72-80. PubMed ID: 24335535
[TBL] [Abstract][Full Text] [Related]
2. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
3. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).
Wong DF; Rosenberg PB; Zhou Y; Kumar A; Raymont V; Ravert HT; Dannals RF; Nandi A; Brasić JR; Ye W; Hilton J; Lyketsos C; Kung HF; Joshi AD; Skovronsky DM; Pontecorvo MJ
J Nucl Med; 2010 Jun; 51(6):913-20. PubMed ID: 20501908
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
Siderowf A; Pontecorvo MJ; Shill HA; Mintun MA; Arora A; Joshi AD; Lu M; Adler CH; Galasko D; Liebsack C; Skovronsky DM; Sabbagh MN
BMC Neurol; 2014 Apr; 14():79. PubMed ID: 24716655
[TBL] [Abstract][Full Text] [Related]
5. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography.
Rosenberg PB; Wong DF; Edell SL; Ross JS; Joshi AD; Brašić JR; Zhou Y; Raymont V; Kumar A; Ravert HT; Dannals RF; Pontecorvo MJ; Skovronsky DM; Lyketsos CG
Am J Geriatr Psychiatry; 2013 Mar; 21(3):272-8. PubMed ID: 23395194
[TBL] [Abstract][Full Text] [Related]
6. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study.
Planton M; Saint-Aubert L; Raposo N; Payoux P; Salabert AS; Albucher JF; Olivot JM; Péran P; Pariente J
J Alzheimers Dis; 2020; 73(4):1607-1614. PubMed ID: 31958082
[TBL] [Abstract][Full Text] [Related]
7. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
8. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies.
Gupta HV; Beach TG; Mehta SH; Shill HA; Driver-Dunckley E; Sabbagh MN; Belden CM; Liebsack C; Dugger BN; Serrano GE; Sue LI; Siderowf A; Pontecorvo MJ; Mintun MA; Joshi AD; Adler CH
J Alzheimers Dis; 2021; 80(4):1603-1612. PubMed ID: 33720879
[TBL] [Abstract][Full Text] [Related]
10. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls.
Newberg AB; Arnold SE; Wintering N; Rovner BW; Alavi A
J Nucl Med; 2012 Jun; 53(6):902-7. PubMed ID: 22577238
[TBL] [Abstract][Full Text] [Related]
11. Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid.
Beach TG; Schneider JA; Sue LI; Serrano G; Dugger BN; Monsell SE; Kukull W
J Neuropathol Exp Neurol; 2014 Oct; 73(10):948-53. PubMed ID: 25192053
[TBL] [Abstract][Full Text] [Related]
12. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
[TBL] [Abstract][Full Text] [Related]
13. Use of florbetapir-PET for imaging beta-amyloid pathology.
Clark CM; Schneider JA; Bedell BJ; Beach TG; Bilker WB; Mintun MA; Pontecorvo MJ; Hefti F; Carpenter AP; Flitter ML; Krautkramer MJ; Kung HF; Coleman RE; Doraiswamy PM; Fleisher AS; Sabbagh MN; Sadowsky CH; Reiman EP; Zehntner SP; Skovronsky DM;
JAMA; 2011 Jan; 305(3):275-83. PubMed ID: 21245183
[TBL] [Abstract][Full Text] [Related]
14. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
[TBL] [Abstract][Full Text] [Related]
15. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
16. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
Camus V; Payoux P; Barré L; Desgranges B; Voisin T; Tauber C; La Joie R; Tafani M; Hommet C; Chételat G; Mondon K; de La Sayette V; Cottier JP; Beaufils E; Ribeiro MJ; Gissot V; Vierron E; Vercouillie J; Vellas B; Eustache F; Guilloteau D
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):621-31. PubMed ID: 22252372
[TBL] [Abstract][Full Text] [Related]
17. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
19. Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET.
Hsiao IT; Huang CC; Hsieh CJ; Wey SP; Kung MP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):908-20. PubMed ID: 23412134
[TBL] [Abstract][Full Text] [Related]
20. Amyloid burden in the hippocampus and default mode network: relationships with gray matter volume and cognitive performance in mild stage Alzheimer disease.
Chang YT; Huang CW; Chang YH; Chen NC; Lin KJ; Yan TC; Chang WN; Chen SF; Lui CC; Lin PH; Chang CC
Medicine (Baltimore); 2015 Apr; 94(16):e763. PubMed ID: 25906109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
